CBD Bioavailability: Oral vs. Sublingual Administration Comparison
Abstract
Sublingual CBD administration achieved 35% higher peak plasma concentrations compared to oral capsules, with faster time-to-peak (45 min vs. 2.1 hours) in healthy volunteers. Inhalation showed highest bioavailability (31%) but shortest duration.
Study Summary
This crossover RCT enrolled 24 healthy volunteers to compare pharmacokinetic profiles of CBD across three routes of administration: oral capsules (100mg), sublingual oil (100mg), and vaporized CBD (50mg). Blood samples were collected at 14 time points over 24 hours. Sublingual administration produced Cmax 35% higher than oral capsules (284 vs. 210 ng/mL) with Tmax of 45 min vs. 2.1 hours. Inhalation showed the highest absolute bioavailability (31% vs. 19% sublingual vs. 6% oral) but the shortest duration (t½ = 1.4 hours vs. 4.2 hours sublingual vs. 5.8 hours oral). A high-fat meal increased oral CBD Cmax by 4.4-fold, highlighting the critical importance of food effects. Inter-individual variability was high across all routes (CV 30–60%), with CYP2C19 polymorphisms explaining a significant portion of variability.
Key Findings
- 1Sublingual CBD achieved 35% higher Cmax than oral capsules with faster onset (45 min vs. 2.1 hr)
- 2Inhalation had highest bioavailability (31%) but shortest duration (t½ 1.4 hr)
- 3High-fat meal increased oral CBD absorption 4.4-fold — food timing is clinically significant
- 4High inter-individual variability (CV 30–60%) driven partly by CYP2C19 polymorphisms
- 5Oral route provides longest duration (t½ 5.8 hr) — preferred for sustained effects
Clinical Implications
- Patients should take oral CBD with a high-fat meal to maximize bioavailability
- Sublingual route preferred when faster onset is needed (acute anxiety, breakthrough pain)
- Inhalation appropriate for rapid onset but requires frequent re-dosing
- CYP2C19 genotyping may help explain non-responders and guide dose adjustment
Study Limitations
- Small sample (n=24) healthy volunteers — may not reflect patient populations
- Single-dose study — chronic dosing pharmacokinetics may differ
- Only one CBD dose per route tested; dose-proportionality not established
- Vaporizer device and temperature affect inhalation bioavailability